Elanco, Eli Lilly report strong Q2 results, raise guidance
Elanco Animal Health reported better-than-expected second-quarter results and raised FY26 guidance above estimates, while Eli Lilly also reported better-than-expected second-quarter results and raised FY26 sales guidance, with the midpoint above estimates.
On CNBC’s “ Halftime Report Final Trades,” Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, recommended Netflix, Inc. (NASDAQ: NFLX ). The streaming service’s shares were trading higher on Tuesday, extending a recent rebound as the stock works to reclaim key moving averages. 9% of its portfolio.
Don’t forget to check out our premarket coverage here Bryn Talkington, managing partner of Requisite Capital Management, picked Horizon Kinetics Inflation Beneficiaries ETF (NYSE: INFL ) as her final trade. Stephanie Link, chief investment strategist, head of investment solutions and equity portfolio manager at Hightower Advisors, said Elanco Animal Health Incorporated (NYSE: ELAN ) has very strong fundamentals. Lending support to her choice, Elanco Animal Health, on Aug. 5, reported better-than-expected second-quarter financial results and raised its FY26 guidance above estimates.
Also, the company issued third-quarter sales guidance above estimates. The pet health company reported adjusted earnings of 34 cents, beating the consensus of 27 cents. 313 billion. Joseph M.
Terranova, senior managing director for Virtus Investment Partners, said Eli Lilly and Company (NYSE: LLY ) is about to make a new all-time high. Supporting his view, Eli Lilly reported better-than-expected second-quarter financial results on Aug. 5 and raised its FY26 sales guidance, with the midpoint above estimates. 3% on Tuesday.
64 during the session. 73 on Tuesday. 77 on Tuesday. Read Also: Ackman Looks for Netflix Redemption: Here’s How Much He Could Have Made Holding His 2022 Stake Photo via Shutterstock